Definitive Healthcare Corp. (NASDAQ:DH) Stock Holdings Lowered by Verition Fund Management LLC

Verition Fund Management LLC lowered its position in Definitive Healthcare Corp. (NASDAQ:DH) by 55.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,504 shares of the company’s stock after selling 30,460 shares during the quarter. Verition Fund Management LLC’s holdings in Definitive Healthcare were worth $110,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. bought a new position in Definitive Healthcare during the 2nd quarter valued at $127,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Definitive Healthcare by 31.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock valued at $116,000 after buying an additional 5,083 shares during the period. Principal Financial Group Inc. boosted its stake in Definitive Healthcare by 10.8% during the second quarter. Principal Financial Group Inc. now owns 39,856 shares of the company’s stock valued at $218,000 after buying an additional 3,874 shares in the last quarter. Rhumbline Advisers grew its holdings in Definitive Healthcare by 19.7% during the second quarter. Rhumbline Advisers now owns 83,751 shares of the company’s stock worth $457,000 after acquiring an additional 13,764 shares during the period. Finally, Victory Capital Management Inc. raised its position in Definitive Healthcare by 1.9% in the second quarter. Victory Capital Management Inc. now owns 509,009 shares of the company’s stock worth $2,779,000 after acquiring an additional 9,316 shares in the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Definitive Healthcare

In related news, insider William Moschella sold 45,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total transaction of $211,500.00. Following the completion of the sale, the insider now directly owns 433,830 shares of the company’s stock, valued at approximately $2,039,001. This represents a 9.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 14.84% of the company’s stock.

Definitive Healthcare Stock Down 0.7 %

Shares of Definitive Healthcare stock opened at $4.46 on Tuesday. The stock has a 50-day simple moving average of $4.41 and a 200-day simple moving average of $4.71. Definitive Healthcare Corp. has a 52-week low of $3.19 and a 52-week high of $10.62. The firm has a market cap of $515.23 million, a price-to-earnings ratio of -1.44, a P/E/G ratio of 3.29 and a beta of 1.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49.

Analysts Set New Price Targets

Several research analysts have issued reports on DH shares. BTIG Research began coverage on shares of Definitive Healthcare in a research report on Tuesday, September 17th. They issued a “buy” rating and a $7.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.81.

Definitive Healthcare Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.